Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

NCT06041776 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
EGFR Sensitive Mutation
Adjuvant Therapy

Interventions

DRUG: Befotertinib + Icotinib placebo
DRUG: Icotinib + Befotertinib placebo

Sponsor

Betta Pharmaceuticals Co., Ltd.